Bone remodeling is the process by which the body continuously removes old bone tissue and replaces it with new bone. It is driven by various types of cells, most notably osteoblasts (which secrete new bone) and osteoclasts (which break down bone); osteocytes are also present in bone. Precursors to osteoclasts, called pre-osteoclasts, express surface receptors called RANK (receptor activator of nuclear factor-kappa B). RANK is a member of the tumor necrosis factor receptor (TNFR) superfamily. RANK is activated by RANKL (the RANK-Ligand), which exists as cell surface molecules on osteoblasts. Activation of RANK by RANKL promotes the maturation of pre-osteoclasts into osteoclasts.<unk>  inhibits this maturation of osteoclasts by binding to and inhibiting RANKL.<unk>  mimics the natural action of osteoprotegerin, an endogenous RANKL inhibitor, that presents with decreasing concentrations (and perhaps decreased effectiveness) in patients who are suffering from osteoporosis. This protects bone from degradation, and helps to counter the progression of the disease.
Denosumab
Medronic acid
Zoledronic acid
Alendronic acid
Risedronic acid
Teriparatide
Pamidronic acid
Ibandronic acid